$CLYM News
Last published 6d ago
- 6d agoCLYMClimb Bio, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 6d agoCLYMClimb Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireCLYM116 Phase 1 data in healthy volunteers showed sustained >90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks after a single dose, supporting every-12-week dosing Initiated dosing in NAVIGATE-2
- 1w agoCLYMClimb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and ExpositionGlobeNewswireWELLESLEY HILLS, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that
- 1w agoCLYMClimb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation ConferenceGlobeNewswireWELLESLEY HILLS, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that
- 2w agoCLYMClimb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026GlobeNewswireLow dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anticipated in 2027
- 2w agoCLYMClimb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026GlobeNewswire>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 12 weeks ~33-day half-life NAVIGATE-2 Phase 2 trial enrolling, with initial data expected in
- 2mo agoCLYMClimb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA NephropathyGlobeNewswire~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse events,
- 2mo agoCLYMClimb Bio to Present at Upcoming Investor ConferencesGlobeNewswireWELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that
- 3mo agoCLYMClimb Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireCLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026 Anticipate CLYM116 Phase 2 trial in IgA nephropathy to initiate dosing in Q3 2026 Budoprutug clinical
- 5mo agoCLYMClimb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026GlobeNewswireData demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ongoing in the high
- 5mo agoCLYMClimb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued DevelopmentGlobeNewswireCompany to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer Initiation of CLYM116 dosing in IgAN patients in Mabworks Phase 2 study expected in Q3 2026
- 5mo agoCLYMClimb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026GlobeNewswireWELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced
- 6mo agoCLYMClimb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 CongressGlobeNewswireWELLESLEY HILLS, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced an
- 6mo agoCLYMClimb Bio to Present at Upcoming Investor ConferencesGlobeNewswireWELLESLEY HILLS, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that
- 6mo agoCLYMClimb Bio Reports First Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireRobust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at ERA 2026 with initial
- 6mo agoCLYMClimb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data ReadoutsGlobeNewswireRobust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; Fast Track Designation
- 6mo agoCLYMClimb Bio, Inc. Announces $110.0 Million Private PlacementGlobeNewswireWELLESLEY HILLS, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has entered
- 7mo agoCLYMClimb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026GlobeNewswireWELLESLEY HILLS, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the
- 7mo agoCLYMClimb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous NephropathyGlobeNewswireWELLESLEY HILLS, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that
- 8mo agoCLYMClimb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesGlobeNewswireDosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2
- 9mo agoCLYMClimb Bio to Present at Upcoming Investor ConferencesGlobeNewswireWELLESLEY HILLS, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that
- 10mo agoCLYMClimb Bio Announces Pipeline Progress and Strategic Priorities for 2026GlobeNewswireFirst patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved regulatory clearance
- 11mo agoCLYMClimb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that
- 1y agoCLYMClimb Bio Reports Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswirePrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical trials of budoprutug
- 1y agoCLYMClimb Bio to Present at Upcoming Investor ConferencesGlobeNewswireWELLESLEY HILLS, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its
- 1y agoCLYMClimb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce StrategyGlobeNewswireWELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has
- 1y agoCLYMClimb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025GlobeNewswirePreclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy (IgAN) Long-term follow-up clinical data for
- 1y agoCLYMClimb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial OfficerGlobeNewswireWELLESLEY HILLS, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has
- 1y agoCLYMClimb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgANGlobeNewswireNew preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL monoclonal antibody
- 1y agoCLYMClimb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025GlobeNewswireWELLESLEY HILLS, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the
- 1y agoCLYMUPDATE – Climb Bio to Present at Upcoming September 2025 Investor ConferencesGlobeNewswireWELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its
- 1y agoCLYMClimb Bio to Present at Upcoming September 2025 Investor ConferencesGlobeNewswireWELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its
- 1y agoCLYMClimb Bio Reports Second Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswireClinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the Coming Weeks
- 1y agoCLYMClimb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical OfficerGlobeNewswireDr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial
- 1y agoCLYMClimb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that
- 1y agoCLYMClimb Bio Reports First Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswireClinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) on Track to Initiate in 2025 CLYM116 Progressing Towards Anticipated IND or
- 1y agoFLDCLYMREXSTKS+1Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX, ACBPR NewswireExec Edge announced the formal launch of Exec Edge Research, a platform that will publish detailed initiation notes along with quarterly updates....
- 1y agoABOSCLYMLENZSLDB+1Climb Bio Appoints Seasoned Biotech Leaders to Board of DirectorsGlobeNewswireWELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors.
- 1y agoCLYMClimb Bio to Present at the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswireWELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced that members of its executive team will participate at the 24th Annual Needham Healthcare Conference being held
- 1y agoCLYMClimb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdatesGlobeNewswireReceived Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE)
- 1y agoCLYMClimb Bio to Present at Upcoming Investor ConferencesGlobeNewswireWELLESLEY, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced that members of its executive team will participate in the upcoming investor conferences detailed below. TD Cowen 45th
- 1y agoCLYMClimb Bio Appoints Perrin Wilson, Ph.D., as Chief Business OfficerGlobeNewswireWELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished leader, with over
- 1y agoCLYMClimb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceGlobeNewswireWELLESLEY, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced that members of its executive team will participate at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
- 1y agoCLYMClimb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA NephropathyGlobeNewswireTransaction Expands Climb Bio's Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically Designed to
- 1y agoCLYMNBIClimb Bio to be Added to the Nasdaq Biotechnology IndexGlobeNewswireWELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 – Climb Bio, Inc. (NASDAQ:CLYM) today announced that the company will be added to the NASDAQ Biotech Index (NASDAQ:NBI) as part of the annual
- 1y agoCLYMClimb Bio Reports Third Quarter 2024 Financial Results and Business HighlightsGlobeNewswireAppointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team with the
- 2y agoCLYMClimb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the BoardGlobeNewswireWELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio's Chair of its Board of Directors. Dr. Williams will assume
- 2y agoCLYMClimb Bio to Present at Upcoming Investor ConferencesGlobeNewswireWELLESLEY, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences detailed below.
- 2y agoCLYMClimb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor EventGlobeNewswireCompletes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development in 2025
- 2y agoCLYMClimb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024GlobeNewswireWELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place in San Diego, CA from